Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jefferies Financial
JEF
5
Amazon
AMZN
CN Stock MarketDetailed Quotes
688670 Jiangsu Gdk Biological Technology
- 11.38
- -0.13-1.13%
Market Closed Apr 29 15:00 CST
1.40BMarket Cap-15.65P/E (TTM)
11.45High11.20Low9.57KlotVolume11.40Open11.51Pre Close10.83MTurnover0.78%Turnover RatioLossP/E (Static)123.20MShares19.1352wk High1.11P/B1.40BFloat Cap9.3652wk Low13.81Limit Up123.20MShs Float78.92Historical High9.21Limit Down2.17%Amplitude9.36Historical Low--Dividend TTM11.32Avg Price4.15KlotAsk--Div YieldTTM100Lot Size4.49KlotBid
About Jiangsu Gdk Biological Technology Company
The company is a limited company co-founded by Yu Jun, Zhang Liangbin, Zhang Jianhui, Nie Shenqian, Xia Jianguo, Taizhou Tongze Enterprise Management Consulting Partnership (Limited Partnership), and Taizhou Tongren Enterprise Management Consulting Partnership (Limited Partnership). The company was listed on the Shanghai Stock Exchange on August 2, 2021. The company focuses on human vaccine R&D, production and sales. The company's main products include 10 human vaccine products to prevent 5 infectious diseases, including influenza, rabies, chicken pox, shingles, and pneumonia.
Company Profile
Short Name-A金迪克生物
Company NameJiangsu Gdk Biological Technology Co., Ltd
Listing DateAug 2, 2021
Issue Price55.18
Shares Offered22.00M share(s)
FoundedDec 29, 2008
Chairmanjun yu
Legal Representativejun yu
General Managerjianhui zhang
Secretaryjin zhou
Employees452
ProvinceJiang Su Sheng
Phone0523-86205860
Office AddressNo. 12 Yujin Road, Taizhou City, Jiangsu Province
Zip Code225300
Registered AddressNo. 12 Yujin Road, Taizhou City, Jiangsu Province
Fax0523-86200152
Emailgdk001@gdkbio.com
Websitehttp://www.gdkbio.com
Business License9132129168412218X6
BusinessThe company is a biopharmaceutical enterprise focusing on the R&D, production and sales of human vaccines. Since its establishment, the company has always insisted on the health and safety of the public as the center, and is committed to growing into a world-class Chinese biotechnology company in the field of human vaccines.
Company Executives
- Name
- Position
- Salary
- jun yu
- Chairman, Directors, Core Technical Personnel
- 1.24M
- jianguo xia
- Directors, Deputy General Manager
- 829.30K
- liangbin zhang
- Directors
- --
- shenqian nie
- Directors
- --
- hongxing sun
- Independent Directors, Member of the Remuneration and Assessment Committee, Audit Committee Convener
- 240.00K
- jianqiang guan
- Independent Directors
- 240.00K
- rong shao
- Independent Directors
- 240.00K
- jin zhou
- Board Secretary
- 857.10K
- huahai tan
- Securities Affairs Representative
- --
- dachang wei
- Chairman of the Supervisory Board, Auditors
- 526.30K
- ling huang
- Auditors
- 120.00K
- jianhui zhang
- General Manager
- 1.74M
- bin song
- Deputy General Manager
- 1.01M
- guoxiong tian
- Deputy General Manager
- 847.80K
- jingyu zou
- Deputy General Manager
- 834.30K
- qiang huang
- Chief Financial Officer
- 629.20K
- yimin zhang
- Head of Audit Department
- --
- jianhua wu
- Core Technical Personnel
- 622.50K
- huicheng yu
- Employee Supervisors
- 79.60K
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts